Clinical Trials Browser

Pathologic Complete Response × Sulindac × Other hematologic neoplasm × Clear all

NCT01843179 2017-02-17

Sulindac for Patients With AML

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute